Control of dyslipidemia in the prevention of recurrent ischemic cerebrovascular accidents (expert opinion)

On July 6, 2022, an interdisciplinary meeting of the Expert Council was held on the topic "Control of dyslipidemia in the prevention of acute and recurrent ischemic cerebrovascular accidents". The conclusion of the Expert Council was that after verification of a lipid metabolism abnormality, in patients with ischemic stroke (IS) and transient ischemic attack (TIA) it is recommended to start or continue statin therapy as early as possible. For secondary prevention of IS, it is necessary to achieve the target level of low-density lipoprotein cholesterol (LDL-C) set for each category of cardiovascular risk, with consistent administration of the maximum tolerated dose of statins with biochemical monitoring of the effectiveness and safety of therapy in the interval of 4–12 weeks. The insufficient effectiveness of statins requires the inclusion of ezetimibe therapy and the decision to increase the dose of statins; in case of intolerance to statins and / or contraindications to their administration, early administration of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors: evolocumab, alirocumab – or an PCSK9 synthesis inhibitor, inclisiran, should be considered. At a LDL-C level of >5.0 mmol/l in patients of the extreme or very high risk group who have had atherothrombotic IS / TIA, necessary administration of a combination including a statin, ezetimibe and an PCSK9 inhibitor (evolocumab, alirocumab) or a PCSK9 synthesis inhibitor (inclisiran) should be considered as early as possible.

1. The Stroke Action Plan for Europe (SAP-E) is a pan-European initiative that was outlined by the European Stroke Organisation (ESO) and the Stroke Alliance for Europe (SAFE). Available from: https://esostroke.org/projects/stroke-actionplan/#:~:text=The%20Stroke%20Action%20Plan%20for,the%20continent%20run%20until%202030

2. Pasport natsional_nogo proyekta «Zdravookhraneniye» (utverzhden prezidiumom Soveta pri Prezidente RF po strategicheskomu razvitiyu i obshchestvennomu proyektu, protokol ot 24.12.2018 № 16) [Passport of the national project "Healthcare" (approved by the Presidium of the Council under the President of the Russian Federation for strategic development and public project, protocol dated December 24, 2018 No. 16)] Available from: http://static.government.ru/media/files/gWYJ4OsAhPOweWaJk1prKDEpregEcduI.pdf (In Russ.)

3. Stahmeyer JT, Stubenrauch S, Geyer S, et al. The Frequency and Timing of Recurrent Stroke: An Analysis of Routine Health Insurance Data. Dtsch Arztebl Int. 2019 Oct 18;116(42):711-7. doi:10.3238/arztebl.2019.0711

4. Lovett JK, Coull AJ, Rothwell PM. Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies. Neurology. 2004 Feb 24;62(4):569-73. doi:10.1212/01.wnl.0000110311.09970.83

5. Grau AJ, Weimar C, Buggle F, et al. Risk factors, outcome, and treatment in subtypes of ischemic stroke: the German stroke data bank. Stroke. 2001 Nov;32(11):2559-66. doi:10.1161/hs1101.098524

6. Oganov RG, Simanenkov VI, Bakulin IG, et al. Comorbidities in clinical practice. Algorithms for diagnostics and treatment. Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention. 2019;18(1):5-66. doi:10.15829/1728-8800-2019-1-5-66 (In Russ.)

7. Cholesterol Treatment Trialists' (CTT) Collaboration; Baigent C, Blackwell L, Pedersen TR, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010 Nov 13;376(9753):1670-81. doi:10.1016/S0140-6736(10)61350-5. Epub 2010 Nov 8.

8. Prikaz Ministerstva zdravookhraneniya Rossiyskoy Federatsii ot 15.03.2022 № 168n “Ob utverzhdenii poryadka provedeniya dispansernogo nablyudeniya za vzroslymi” [Order of the Ministry of Health of the Russian Federation dated March 15, 2022 No. 168n “On approval of the procedure for dispensary observation of adults”] (In Russ.)

9. Bulwa ZB, Mendelson SJ, Brorson JR. Acute Secondary Prevention of Ischemic Stroke: Overlooked No Longer. Front Neurol. Front Neurol. 2021 Sep 10;12:701168. doi:10.3389/fneur.2021.701168

10. Klinicheskiye rekomendatsii «Ishemicheskiy insul’t i tranzitornaya ishemicheskaya ataka u vzroslykh», ID:171, 2021 g. [Clinical guidelines "Ischemic stroke and transient ischemic attack in adults", ID: 171, 2021]. Available from: https://cr.minzdrav.gov.ru/recomend/171_2 (In Russ.)

11. Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2021 Jul;52(7):e364-e467. doi:10.1161/STR.0000000000000375. Epub 2021 May 24. Erratum in: Stroke. 2021 Jul;52(7):e483-e484.

12. Kang J, Kim N, Park TH, et al. Early statin use in ischemic stroke patients treated with recanalization therapy: retrospective observational study. BMC Neurol. 2015 Jul 30;15:122. doi:10.1186/s12883-015-0367-4

13. Jeong HG, Kim BJ, Yang MH, et al. Early statins after intravenous or endovascular recanalization is beneficial regardless of timing, intensity and stroke mechanism. J Stroke. 2017 Sep;19(3):370-2. doi:10.5853/jos.2017.00836. Epub 2017 Sep 29.

14. Kastelein JJ, Akdim F, Stroes ES, et al; ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008 Apr 3;358(14):1431-43. doi:10.1056/NEJMoa0800742. Epub 2008 Mar 30. Erratum in: N Engl J Med. 2008 May 1;358(18):1977.

15. Catapano AL, Graham I, De Backer G, et al; ESC Scientific Document Group. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. 2016 Oct 14;37(39):2999-3058. doi:10.1093/eurheartj/ehw272. Epub 2016 Aug 27.

16. Obshchaya kharakteristika lekarstvennogo preparata Sibrava. RU LP-№(000689)-(RG-RU) [General characteristics of the drug Sibrava. RU LP-No. (000689)-(RG-RU)] (In Russ.)

17. Ray KK, Wright RS, Kallend D, et al.; ORION-10 and ORION-11 Investigators. Two phase 3 trials of Inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020 Apr 16;382(16):1507-19. doi:10.1056/NEJMoa1912387. Epub 2020 Mar 18.

18. Raal FJ, Kallend D, Ray KK, et al; ORION-9 Investigators. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. N Engl J Med. 2020 Apr 16;382(16):1520-30. doi:10.1056/NEJMoa1913805. Epub 2020 Mar 18.

19. Khan SA, Naz A, Qamar Masood M, Shah R. Meta-Analysis of Inclisiran for the Treatment of Hypercholesterolemia. Am J Cardiol. 2020 Nov 1;134:69-73. doi:10.1016/j.amjcard.2020.08.018. Epub 2020 Aug 15.